Research and Application of Stem Cell-Based Therapy in Idiopathic Pulmonary Fibrosis: A Review

FENG Xiao-rong, YAO Jie, WU Ya, CHENG Xia, ZOU Ping-jin, WANG Hua, YANG Mu

Abstract

Idiopathic pulmonary fibrosis (IPF) is a type of pulmonary disease that progresses acutely or slowly into irreversible pulmonary diseases, resulting in the end severe damages to patients' lung functions, as well as deaths. At present, the pathogenesis of pulmonary fibrosis is still not clear and there is no effective therapeutic measure available to control the progression of the disease. Research findings indicate that stem cells, being the origin of all cells of organisms, participate in the development of individuals at various stages and play an important role in repairing pulmonary tissue damage. Stem cells are attracting growing attention in the field of regenerative medicine, providing new ideas for treating IPF with transplanted stem cells. Herein, in order to better explore the potential applications of stem cell transplantation in treating IPF, we attempt to summarize preliminary studies of stem cell-mediated pulmonary remodeling after IPF, as well as cutting-edge clinical trials in stem cell-based IPF therapy.

 

Keywords: Idiopathic pulmonary fibrosis, Stem cell transplantation therapy, Directional differentiation, Tissue microenvironment

 

Full Text:

PDF


References


VAN CLEEMPUT J， SONAGLIONI A， WUYTS W A， et al. Idiopathic pulmonary fibrosis for cardiologists: differential diagnosis, cardiovascular comorbidities, and patient management. Adv Ther，2019，36(2): 298–317.

RAGHU G， REMY-JARDIN M， MYERS J L， et al. Diagnosis of idiopathic pulmonary fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med， 2018， 198 (5): e44− e68[2021-03-24]. https://pubmed.ncbi.nlm.nih.gov/30168753/. doi: 10.1164/rccm.201807-1255ST.

WYNN T A， RAMALINGAM T R. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med，2012，18(7): 1028–1040. WYNN T A. Cellular and molecular mechanisms of fibrosis. J Pathol， 2008，214(2): 199–210.

BLOKLAND KEC， WATERS D W， SCHULIGA M， et al. Senescence of IPF lung fibroblasts disrupt alveolar epithelial cell proliferation and promote migration in wound healing. Pharmaceutics，2020，12(4): 389.

MYLLARNIEMI M， KAARTEENAHO R. Pharmacological treatment of idiopathic pulmonary fibrosis - preclinical and clinical studies of pirfenidone， nintedanib， and N-acetylcysteine. Eur Clin Respir J， 2015， 2[2021-03-24]. https://pubmed.ncbi.nlm.nih.gov/26557253/. doi: 10.3402/ecrj.v2.26385.

RAGHU G， SELMAN M. Nintedanib and pirfenidone. New antifibrotic treatments indicated for idiopathic pulmonary fibrosis offer hopes and raises questions. Am J Respir Crit Care Med，2015，191(3): 252–254.

GUPTA N， SU X， POPOV B， et al. Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice. J Immunol， 2007，179(3): 1855–1863.

KANG J S， SUH Y J， MOON K H， et al. Clinical efficiency of bone marrow mesenchymal stem cell implantation for osteonecrosis of the femoral head: A matched pair control study with simple core decompression. Stem Cell Res Ther，2018，9(1): 274.

URBIETA-CACERES V H， ZHU X Y， JORDAN K L， et al. Selective improvement in renal function preserved remote myocardial microvascular integrity and architecture in experimental renovascular disease. Atherosclerosis，2012，221(2): 350–358.

CHUGH A R， BEACHE G M， LOUGHRAN J H， et al. Administration of cardiac stem cells in patients with ischemic cardiomyopathy: the SCIPIO trial: surgical aspects and interim analysis of myocardial function and viability by magnetic resonance. Circulation，2012，126(11 Suppl 1): S54–S64.

GLASSBERG M K， MINKIEWICZ J， TOONKEL R L， et al. Allogeneic human mesenchymal stem cells in patients with idiopathic pulmonary fibrosis via intravenous delivery (AETHER): A phase I safety clinical trial. Chest，2017，151(5): 971–981.

GHADIRI M， YOUNG P M， TRAINI D. Cell-based therapies for the treatment of idiopathic pulmonary fibrosis (IPF) disease. Expert Opin Biol Ther，2016，16(3): 375–387.

SERRANO-MOLLAR A， NACHER M， GAY-JORDI G， et al. Intratracheal transplantation of alveolar type II cells reverses bleomycin-induced lung fibrosis. Am J Respir Crit Care Med，2007，176(12): 1261–1268.

ZHOU Q， YE X， SUN R， et al. Differentiation of mouse induced pluripotent stem cells into alveolar epithelial cells in vitro for use in vivo. Stem Cells Transl Med，2014，3(6): 675–685.

MA N， GAI H， MEI J， et al. Bone marrow mesenchymal stem cells can differentiate into type II alveolar epithelial cells in vitro. Cell Biol Int， 2011，35(12): 1261–1266.

UZUNHAN Y， NUNES H， GILLE T， et al. Innovative therapeutics for idiopathic pulmonary fibrosis. Presse Med，2011，40(12 Pt 1): 1100–1112.

JEONG J O， HAN J W， KIM J M， et al. Malignant tumor formation after transplantation of short-term cultured bone marrow mesenchymal stem cells in experimental myocardial infarction and diabetic neuropathy. Circ Res，2011，108(11): 1340–1347.

CARDENES N， ALVAREZ D， SELLARES J， et al. Senescence of bone marrow-derived mesenchymal stem cells from patients with idiopathic pulmonary fibrosis. Stem Cell Res Ther，2018，9(1): 257.

YAMADA M， KUBO H， KOBAYASHI S， et al. Bone marrow-derived progenitor cells are important for lung repair after lipopolysaccharide-induced lung injury. J Immunol，2004，172(2): 1266–1272.

ORTIZ L A， GAMBELLI F， MCBRIDE C， et al. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci U S A，2003，100(14): 8407–8411.

ZUO W， ZHANG T， WU D Z， et al. p63+Krt5+ distal airway stem cells are essential for lung regeneration. Nature，2015，517(7536): 616–620.

CHEN X， SHI C， CAO H， et al. The hedgehog and Wnt/beta-catenin system machinery mediate myofibroblast differentiation of LR-MSCs in pulmonary fibrogenesis. Cell Death Dis，2018，9(6): 639.

XI Y， KIM T， BRUMWELL A N， et al. Local lung hypoxia determines epithelial fate decisions during alveolar regeneration. Nat Cell Biol，2017， 19(8): 904–914.

CHEN X， ZHAO C， ZHANG C， et al. Vagal-alpha7nAChR signaling promotes lung stem cells regeneration via fibroblast growth factor 10 during lung injury repair. Stem Cell Res Ther，2020，11(1): 230.

NABHAN A N， BROWNFIELD D G， HARBURY P B， et al. Single-cell Wnt signaling niches maintain stemness of alveolar type 2 cells. Science， 2018，359(6380): 1118–1123.

SUN T， HUANG Z， ZHANG H， et al. TAZ is required for lung alveolar epithelial cell differentiation after injury. JCI Insight， 2019， 5 [2021-03-24]. https://pubmed.ncbi.nlm.nih.gov/31211697/. doi: 10.1172/jci. insight.128674.

IMAJO M， MIYATAKE K， IIMURA A， et al. A molecular mechanism that links Hippo signalling to the inhibition of Wnt/beta-catenin signalling. EMBO J，2012，31(5): 1109–1122.

CAO H， WANG C， CHEN X， et al. Inhibition of Wnt/beta-catenin signaling suppresses myofibroblast differentiation of lung resident mesenchymal stem cells and pulmonary fibrosis. Sci Rep，2018，8(1): 13644.

TAN J L， LAU S N， LEAW B， et al. Amnion epithelial cell-derived exosomes restrict lung injury and enhance endogenous lung repair. Stem Cells Transl Med，2018，7(2): 180–196.

CHEN Y B， SHAH N N， RENTERIA A S， et al. Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood Adv，2019，3(23): 4136–4146.

LE GOUILL S， THIEBLEMONT C， OBERIC L， et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med，2017，377(13): 1250–1260.

KRAMPERA M， COSMI L， ANGELI R， et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells，2006，24(2): 386–398.


Refbacks

  • There are currently no refbacks.